Back

Title
  • en Serum myostatin levels are independently associated with skeletal muscle wasting in patients with heart failure
Creator
Accessrights open access
Rights
  • en © 2016. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
  • https://creativecommons.org/licenses/by-nc-nd/4.0/
  • en Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
Subject
  • Other en Heart failure
  • Other en Myostatin
  • Other en Muscle wasting
  • NDC 490
Description
  • Abstract en Background: It has been reported that skeletal muscle mass and strength are decreased in patients with heart failure (HF), and HF is associated with both reduced exercise capacity and adverse clinical outcomes. Myostatin has been known as a negative regulator of muscle growth, follistatin as the myostatin antagonist, maintaining tissue homeostasis. We thus determined serum myostatin levels in HF patients and whether they are associated with skeletal muscle wasting. Methods and results: Forty one consecutive HF patients (58 +/- 15 years old, New York Heart Association class I-III) and 30 age-matched healthy subjects as controls (53 +/- 8 years old) were studied. Serum myostatin levels were significantly lower in HF patients than controls (18.7 +/- 7.4 vs. 23.6 +/- 5.2 ng/mL, P < 0.001). Circumference of the thickest part of the right thigh was significantly small (468 +/- 72 vs. 559 +/- 37 mm, P = 0.001) and lower extremity muscular strength was lower in patients with HF (129 +/- 55 vs. 219 +/- 52 N × m, P < 0.001). Fourteen HF patients (34%) had muscle wasting. By univariate analysis, higher age, higher serum follistatin, and lower serum myostatin were significantly associated with the presence of muscle wasting. By multivariate analysis, serum myostatin levels were independently associated with muscle wasting (OR = 0.77, 95% CI [0.58, 0.93], P = 0.02). Conclusion: Serum myostatin levels were significantly decreased in HF patients and associated with lower extremity muscle wasting, suggesting that myostatin may be an important factor for maintaining skeletal muscle mass and strength in HF.
Publisher en Elsevier
Date
    Issued2016-10-01
Language
  • eng
Resource Type journal article
Version Type AM
Identifier HDL http://hdl.handle.net/2115/67234
Relation
  • isVersionOf DOI https://doi.org/10.1016/j.ijcard.2016.06.231
  • PMID 27390974
Journal
    • PISSN 0167-5273
      • en International journal of cardiology
      • Volume Number220 Page Start483 Page End487
File
Oaidate 2023-07-26